CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Rating of "Buy" by Brokerages

Key Points

• CryoPort, Inc. has received an average rating of "Buy" from ten analysts, with a consensus price target set at $12.00.
• Insider trading activity includes CEO Jerrell Shelton selling over 151,000 shares for approximately $1 million, indicating a 14.22% decrease in his position.
• Institutional investors now hold about 92.90% of CryoPort's shares, with notable increases in holdings from several hedge funds in the past quarter.

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) have earned an average rating of "Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $12.00.

A number of research firms have recently weighed in on CYRX. BTIG Research cut their price objective on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of CryoPort in a research report on Thursday, May 8th. Stephens started coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price target for the company. Leerink Partners raised shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price for the company in a research note on Wednesday, August 6th. Finally, Leerink Partnrs raised shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 6th.

Insider Activity

In related news, CEO Jerrell Shelton sold 151,304 shares of the business's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $6.81, for a total transaction of $1,030,380.24. Following the completion of the sale, the chief executive officer owned 912,419 shares of the company's stock, valued at $6,213,573.39. This represents a 14.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert Stefanovich sold 9,300 shares of the company's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the completion of the transaction, the chief financial officer owned 207,213 shares of the company's stock, valued at approximately $1,796,536.71. This trade represents a 4.30% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 492,247 shares of company stock worth $3,384,579. 10.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC lifted its holdings in shares of CryoPort by 299.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock worth $27,000 after acquiring an additional 2,729 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its position in shares of CryoPort by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after buying an additional 2,120 shares during the period. Tower Research Capital LLC TRC boosted its stake in CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. Lazard Asset Management LLC bought a new position in CryoPort during the 4th quarter worth approximately $51,000. Finally, SBI Securities Co. Ltd. boosted its stake in CryoPort by 548,750.0% during the 1st quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock worth $67,000 after acquiring an additional 10,975 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.

CryoPort Stock Performance

Shares of CYRX stock opened at $8.50 on Thursday. The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39. CryoPort has a 52-week low of $4.58 and a 52-week high of $9.48. The business has a 50-day simple moving average of $7.94 and a 200-day simple moving average of $6.75. The stock has a market cap of $425.60 million, a PE ratio of 6.39 and a beta of 1.62.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The business had revenue of $45.45 million during the quarter, compared to analysts' expectations of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. On average, equities analysts expect that CryoPort will post -0.99 EPS for the current year.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.